High urine IP-10 levels associate with chronic HCV infection

Journal of Infection

Volumn 68, Issue 6, 2014, Pages 591-600

  Petrone, Linda ^a   Chiacchio, Teresa ^a   Vanini, Valentina ^a   Petruccioli, Elisa ^a   Cuzzi, Gilda ^a   Di Giacomo, Cristina ^b   Pucci, Luigia ^b   Montalbano, Marzia ^b   Lionetti, Raffaella ^b   Testa, Angela ^b   Lapa, Daniele ^b   Navarra, Assunta ^b   Visco Comandini, Ubaldo ^b   Goletti, Delia ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b INMI   (Italy)

Author keywords

Biomarkers; Cured HCV subjects; HCV; IP 10; PnALT; Serum; SVR; Urine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; CYTOLYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IL 28B GENE; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; CHEMISTRY; MIDDLE AGED; PATHOLOGY; SERUM; URINE;

ADULT; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SERUM; URINE;

EID: 84899908852     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.02.008     Document Type: Article

References (29)

1. WHO Fact sheet on hepatitis C 2013, 164. Updated 2013.
2. Zuccaro O, Tosti ME, Mele A, Spada E, SEIEVA Collaborative Group. Epidemiology of acute viral hepatitis in Italy: results of the surveillance through SEIEVA (Sistema Epidemiologico Integrato dell'Epatite Virale Acuta). Rome: Istituto Superiore di Sanità. Rapporti ISTISAN 12/4 2012.
3. Kondo Y., Ueno Y., Shimosegawa T. Dysfunction of immune systems and host genetic factors in hepatitis C virus infection with persistent normal ALT. Hepat Res Treat 2011, 2011:713216.
4. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
5. Jacobson I.M., Mchutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
6. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
7. Lagging M., Askarieh G., Negro F., Bibert S., Soderholm J., Westin J., et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011, 6:e17232.
8. Darling J.M., Aerssens J., Fanning G., Mchutchison J.G., Goldstein D.B., Thompson A.J., et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011, 53:14-22.
9. Beinhardt S., Aberle J.H., Strasser M., Dulic-Lakovic E., Maieron A., Kreil A., et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012, 142:78-85.e2.
10. You C.R., Park S.H., Jeong S.W., Woo H.Y., Bae S.H., Choi J.Y., et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver 2011, 5:506-512.
11. Askarieh G., Alsio A., Pugnale P., Negro F., Ferrari C., Neumann A.U., et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010, 51:1523-1530.
12. Zeremski M., Petrovic L.M., Talal A.H. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007, 14:675-687.
13. Zeremski M., Petrovic L.M., Chiriboga L., Brown Q.B., Yee H.T., Kinkhabwala M., et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48:1440-1450.
14. Zeremski M., Dimova R., Brown Q., Jacobson I.M., Markatou M., Talal A.H. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009, 200:1774-1780.
15. Butera D., Marukian S., Iwamaye A.E., Hembrador E., Chambers T.J., Di Bisceglie A.M., et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005, 106:1175-1182.
16. Casrouge A., Bisiaux A., Stephen L., Schmolz M., Mapes J., Pfister C., et al. Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol 2012, 167:137-148.
17. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011, 121:308-317.
18. Ruhwald M., Dominguez J., Latorre I., Losi M., Richeldi L., Pasticci M.B., et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) 2011, 91:260-267.
19. Kabeer B.S., Raja A., Raman B., Thangaraj S., Leportier M., Ippolito G., et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011, 11:135. 10.1186/1471-2334-11-135.
20. Goletti D., Raja A., Syed Ahamed Kabeer B., Rodrigues C., Sodha A., Carrara S., et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?. PLoS One 2010, 5:e12577.
21. Vanini V., Petruccioli E., Gioia C., Cuzzi G., Orchi N., Rianda A., et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012, 65:49-59.
22. Cannas A., Calvo L., Chiacchio T., Cuzzi G., Vanini V., Lauria F.N., et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 2010, 10:333. 10.1186/1471-2334-10-333.
23. Waikar S.S., Sabbisetti V.S., Bonventre J.V. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010, 78:486-494.
24. Kristal B., Shasha S.M., Labin L., Cohen A. Estimation of quantitative proteinuria by using the protein-creatinine ratio in random urine samples. Am J Nephrol 1988, 8:198-203.
25. Price C.P., Newall R.G., Boyd J.C. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem 2005, 51:1577-1586.
26. Yuksekol I., Ozkan M., Akgul O., Tozkoparan E., Al-Rashed M., Balkan A., et al. Urinary neopterin measurement as a non-invasive diagnostic method in pulmonary tuberculosis. Int J Tuberc Lung Dis 2003, 7:771-776.
27. Zeremski M., Dimova R., Astemborski J., Thomas D.L., Talal A.H. CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis 2011, 204:832-836.
28. Reiberger T., Aberle J.H., Kundi M., Kohrgruber N., Rieger A., Gangl A., et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008, 13:969-976.
29. Proost P., Schutyser E., Menten P., Struyf S., Wuyts A., Opdenakker G., et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.